DORIXINA-FLAM® (f.f. tablet) is composed of a combination of 250 mg of Lysine Clonixinate (CL) and 50 mg of Diclofenac sodium (D). Although both drugs are non-steroidal anti-inflammatory analgesics (NSAIDs), Diclofenac has a predominant anti-inflammatory action, while in the case of lysine clonixinate the predominant action is analgesic.
DORIXINA-FLAM® (f.f. tablet) is designed for those cases in which in addition to relieving pain it is necessary to inhibit the inflammation of the tissues involved.
DORIXINA-FLAM® (f.f. tablet) has the advantage of relieving pain with high efficacy, which is greater than that obtained by administering either medication separately and at the same dose contained in the combination. This has been widely demonstrated in the efficacy studies carried out which are reviewed below.
DORIXINA-FLAM® (f.f. tablet) is indicated in the following cases:
Surgery: Pain in gynecological, orthopedic, urological and general surgery interventions. Post-surgical pain in gynecology.
Traumatology and Orthopedics: Pain due to trauma in general, dislocations, sprains, fractures, myalgias, low back pain, myositis, osteoarthritis, polyarthritis and neuritis.
Gynecology and Urology: Dysmenorrhea, mastalgia, adnexitis, postpartum pain and postepisiotomy, urethritis, cystitis, prostatitis, puerperal pain and urolithiasis.
Dentistry: Stomatitis, Odontalgias (dental extractions and periodontitis).
Proctology and Digestive System: Hemorrhoid pain, fissures, fistulas, proctological surgery and cholelithiasis.
General medicine: Gout, soft tissue disease, headache, otalgia, sinusitis, shingles, neuritis, neuralgia, rheumatic pain.
Oncology: An alternative in pain relief of cancerous origin.
Rheumatology: Gout, acute pictures of rheumatic processes.